These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 10729234)
1. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant. Horner AA; Raz E Clin Immunol; 2000 Apr; 95(1 Pt 2):S19-29. PubMed ID: 10729234 [TBL] [Abstract][Full Text] [Related]
2. Immunostimulatory DNA is a potent mucosal adjuvant. Horner AA; Ronaghy A; Cheng PM; Nguyen MD; Cho HJ; Broide D; Raz E Cell Immunol; 1998 Nov; 190(1):77-82. PubMed ID: 9826449 [TBL] [Abstract][Full Text] [Related]
3. Intranasal administration of CpG oligonucleotides induces mucosal and systemic Type 1 immune responses and adjuvant activity to porcine reproductive and respiratory syndrome killed virus vaccine in piglets in vivo. Zhang L; Tian X; Zhou F Int Immunopharmacol; 2007 Dec; 7(13):1732-40. PubMed ID: 17996683 [TBL] [Abstract][Full Text] [Related]
4. New generation of mucosal adjuvants for the induction of protective immunity. Yuki Y; Kiyono H Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340 [TBL] [Abstract][Full Text] [Related]
5. Novel strategies using DNA for the induction of mucosal immunity. McCluskie MJ; Davis HL Crit Rev Immunol; 1999; 19(4):303-29. PubMed ID: 10530431 [TBL] [Abstract][Full Text] [Related]
6. The adjuvant effect of CpG oligodeoxynucleotide linked to the non-toxic B subunit of cholera toxin for induction of immunity against H. pylori in mice. Nyström-Asklin J; Adamsson J; Harandi AM Scand J Immunol; 2008 May; 67(5):431-40. PubMed ID: 18298617 [TBL] [Abstract][Full Text] [Related]
7. Enhancement of mucosal immune responses by intranasal co-delivery of Newcastle disease vaccine plus CpG oligonucleotide in SPF chickens in vivo. Zhang L; Zhang M; Li J; Cao T; Tian X; Zhou F Res Vet Sci; 2008 Dec; 85(3):495-502. PubMed ID: 18359498 [TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Kodama S; Abe N; Hirano T; Suzuki M Laryngoscope; 2006 Feb; 116(2):331-5. PubMed ID: 16467729 [TBL] [Abstract][Full Text] [Related]
9. Airway peptidoglycan and immunostimulatory DNA exposures have divergent effects on the development of airway allergen hypersensitivities. Chisholm D; Libet L; Hayashi T; Horner AA J Allergy Clin Immunol; 2004 Mar; 113(3):448-54. PubMed ID: 15007346 [TBL] [Abstract][Full Text] [Related]
10. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Abe N; Kodama S; Hirano T; Eto M; Suzuki M Laryngoscope; 2006 Mar; 116(3):407-12. PubMed ID: 16540899 [TBL] [Abstract][Full Text] [Related]
11. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. Kayamuro H; Abe Y; Yoshioka Y; Katayama K; Nomura T; Yoshida T; Yamashita K; Yoshikawa T; Kawai Y; Mayumi T; Hiroi T; Itoh N; Nagano K; Kamada H; Tsunoda S; Tsutsumi Y Biomaterials; 2009 Oct; 30(29):5869-76. PubMed ID: 19646748 [TBL] [Abstract][Full Text] [Related]
12. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Hickey DK; Aldwell FE; Beagley KW Vaccine; 2009 Oct; 27(44):6217-25. PubMed ID: 19698810 [TBL] [Abstract][Full Text] [Related]
13. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556 [TBL] [Abstract][Full Text] [Related]
14. A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens. Lomada D; Gambhira R; Nehete PN; Guhad FA; Chopra AK; Peterson JW; Sastry KJ Vaccine; 2004 Dec; 23(4):555-65. PubMed ID: 15530705 [TBL] [Abstract][Full Text] [Related]
15. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections. Zimmermann S; Dalpke A; Heeg K Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944 [TBL] [Abstract][Full Text] [Related]
16. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice. Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242 [TBL] [Abstract][Full Text] [Related]
18. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356 [TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Cho HJ; Takabayashi K; Cheng PM; Nguyen MD; Corr M; Tuck S; Raz E Nat Biotechnol; 2000 May; 18(5):509-14. PubMed ID: 10802617 [TBL] [Abstract][Full Text] [Related]
20. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines. Rieger R; Kipps TJ Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]